KMT2D gene that drives lung cancer development offers fresh insight into how the lung carcinoma might be treated.
There is currently no approved, targeted, first-line therapy for lung squamous carcinoma (LUSC), a cancer that forms in cell layers lining the organ and is responsible for 20 to 30 percent of lung carcinoma deaths. But a new study, publishing in iCancer Cell,/i found that deleting a gene called KMT2D caused normal (basal) lung cells grown in complex cultures called organoids to transform into LUSC cells....
KMT2D gene that drives lung cancer development offers fresh insight into how the lung carcinoma might be treated.
There is currently no approved, targeted, first-line therapy for lung squamous carcinoma (LUSC), a cancer that forms in cell layers lining the organ and is responsible for 20 to 30 percent of lung carcinoma deaths. But a new study, publishing in iCancer Cell,/i found that deleting a gene called KMT2D caused normal (basal) lung cells grown in complex cultures called organoids to transform into LUSC cells....